Skip to main content
Amylyx Care Team

Amylyx has started a process with the FDA and Health Canada to discontinue the marketing authorizations for RELYVRIO®/ALBRIOZA™ and remove the product from the market in the U.S. and Canada. As of April 4, 2024, RELYVRIO/ALBRIOZA is not available for new patients. Patients on therapy as of April 4 in the U.S. and Canada who, in consultation with their physician, wish to continue can be transitioned to a free drug program.​

To contact the Amylyx Care Team for further assistance, call 866-318-2989 or email

Medical Information